José Luis Barranco Quintana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
José Luis Barranco Quintana has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Farouk Allam
Ain Shams University
2 shared publications A S Del Castillo
1 shared publicationA. Bulnes-Ramos
Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío/CSIC/University of Sevilla, Seville, Spain
1 shared publicationA. Eworo
1 shared publicationA. Gasch
1 shared publicationA. Moreno
University Clinic Hospital, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 23 September 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 887-910
Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024
Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies. Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.
- 23 September 2024
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 887-910
Open AccessVaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024
Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies. Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.
- 1 June 2016
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 39 (6) , 385-392
Adherence to a predefined vaccination program in patients with inflammatory bowel disease
- 1 June 2016
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 39 (6) , 385-392
Adherence to a predefined vaccination program in patients with inflammatory bowel disease
- 1 November 2015
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 21 (11) , 1040.e11-1040.e18
Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe
- 1 November 2015
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 21 (11) , 1040.e11-1040.e18
Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe
- 27 March 2007
- Vol. 44 (6) , 381-2
[Neurodegenerative diseases and tea].
- 1 January 2007
- Published by Taylor & Francis in Neurological Research
- Vol. 29 (1) , 91-95
Alzheimer's disease and coffee: a quantitative review
To estimate the pooled risk of coffee consumption for Alzheimer's disease (AD). We have reviewed all observational studies that evaluated the association between AD risk and coffee consumption. Four studies were identified: two case-control studies and two cohorts. These studies were carried out between 1990 and 2002. There was an obvious protective effect of coffee consumption in the pooled estimate [risk estimate: 0.73 (95% confidence interval: 0.58-0.92)]. However, the homogeneity test was highly significant (p<0.01), indicating heterogeneity across the pooled studies. Pooled analysis applying the random effect model was 0.79 with 95% confidence interval overlapping unity (95% confidence interval: 0.46-1.36). Three studies assessed coffee consumption by interview questionnaire. The risk of AD in coffee consumers versus non-consumers in studies that used interview questionnaire had a pooled risk estimate of 0.70 with 95% confidence interval 0.55-0.90. Although our pooled estimates show that coffee consumption is inversely associated with the risk of AD, the four studies had heterogeneous methodologies and results. Further prospective studies evaluating the association between coffee consumption and AD are strongly needed.
- 1 January 2007
- Published by Taylor & Francis in Neurological Research
- Vol. 29 (1) , 91-95
Alzheimer's disease and coffee: a quantitative review
To estimate the pooled risk of coffee consumption for Alzheimer's disease (AD). We have reviewed all observational studies that evaluated the association between AD risk and coffee consumption. Four studies were identified: two case-control studies and two cohorts. These studies were carried out between 1990 and 2002. There was an obvious protective effect of coffee consumption in the pooled estimate [risk estimate: 0.73 (95% confidence interval: 0.58-0.92)]. However, the homogeneity test was highly significant (p<0.01), indicating heterogeneity across the pooled studies. Pooled analysis applying the random effect model was 0.79 with 95% confidence interval overlapping unity (95% confidence interval: 0.46-1.36). Three studies assessed coffee consumption by interview questionnaire. The risk of AD in coffee consumers versus non-consumers in studies that used interview questionnaire had a pooled risk estimate of 0.70 with 95% confidence interval 0.55-0.90. Although our pooled estimates show that coffee consumption is inversely associated with the risk of AD, the four studies had heterogeneous methodologies and results. Further prospective studies evaluating the association between coffee consumption and AD are strongly needed.